Th1 Adaptive Immune Responses in Cardiac Graft Arteriosclerosis
Author(s) -
George Tellides
Publication year - 2006
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.106.651521
Subject(s) - medicine , arteriosclerosis , immunosuppression , transplantation , immune system , immunology , acquired immune system , pathology , cardiology
Heart transplants are not rejected in the absence of adaptive immune responses, eg, in transplantations between genetically identical donors and hosts or to recipients with severe combined immunodeficiencies. Activation of adaptive immunity to an allograft causes destructive responses against donor parenchymal or vascular cells, called acute rejection. In the presence of adequate immunosuppression, acute rejection is suppressed; however, chronic rejection may occur, manifesting as conduit arterial lumen loss resulting from expansion of the tunica intima and remodeling of vessel size, called graft arteriosclerosis.1 The differences in pathological findings and in sensitivity to immunosuppressive agents suggest that chronic graft failure arises from different mechanisms operative in separate allograft compartments than in acute graft rejection. The precise pathogenesis of graft arteriosclerosis is unknown, although there is broad consensus that it is, at least in part, an alloimmune process in that the arteriosclerotic changes are limited to the vascular bed of the allograft and spare the host vasculature. Adaptive immunity may activate a variety of effector mechanisms that cause chronic graft rejection in murine transplantation models.1 Although it is not the only factor that can cause graft arteriosclerosis, the evidence for the signature Th1 cytokine, interferon (IFN)-γ, is particularly compelling. In mouse transplantation models, serological neutralization or the genetic absence of IFN-γ reduces intimal expansion of graft arteries.2,3 Moreover, in a chimeric human-mouse model, antibody neutralization of IFN-γ prevents allogeneic T cell–mediated endothelial dysfunction, intimal thickening, and outward vascular remodeling; administration of IFN-γ accelerates these effects; and exogenous IFN-γ in the absence of leukocytes is sufficient to cause the arteriosclerotic changes.4–6 However, definitive evidence for a pathogenetic role of IFN-γ in clinical cardiac transplantation is lacking.Articles pp 1599 and 1608 In this issue of Circulation , van Loosdregt et al7 performed a comprehensive inventory of cytokines, chemokines, …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom